Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06764875 · ClinicalTrials.gov registry record · Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
A Phase 3 study of Gastroesophageal Junction Adenocarcinoma and HER2-positive Gastric Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 840
- Enrollment target
- 20
- Study locations
NCT06764875 is a Phase 3 study of Gastroesophageal Junction Adenocarcinoma and HER2-positive Gastric Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 840 participants, above the 383-participant average among 40 other Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (119% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT06764875, a Phase 3 study of Gastroesophageal Junction Adenocarcinoma and HER2-positive Gastric Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 840 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Trastuzumab
- DRUG Trastuzumab deruxtecan
- DRUG Rilvegostomig
- DRUG 5-fluorouracil
Study Locations (20)
California
- Research Site - Duarte
- Research Site - La Jolla
- Research Site - Los Alamitos
- Research Site - Los Angeles
- Research Site - Santa Monica
- Research Site - Solvang
- Research Site - Upland
- Research Site - Walnut Creek
Illinois
- Research Site - Chicago
- Research Site - Chicago
- Research Site - Evanston
- Research Site - Hinsdale
- Research Site - Niles
Florida
- Research Site - Jacksonville
- Research Site - Orlando
Alaska
- Research Site - Anchorage
Arizona
- Research Site - Phoenix
Colorado
- Research Site - Aurora
Georgia
- Research Site - Marietta
Indiana
- Research Site - Dyer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2025-03-01 |
| Est. Completion | 2030-12-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06764875
The ClinicalTrials.gov registry entry for NCT06764875 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 840 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 383-participant average among 40 other Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (119% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastroesophageal Junction Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06764875 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT06764875 about?
NCT06764875 is a clinical study titled "A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer". This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or...
What is the current status of trial NCT06764875?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 2025-03-01. Estimated completion is 2030-12-09.
What conditions does trial NCT06764875 study?
This clinical trial studies the following conditions: Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer.
What interventions are being tested in trial NCT06764875?
The interventions under investigation include: Pembrolizumab (DRUG), Trastuzumab (DRUG), Trastuzumab deruxtecan (DRUG), Rilvegostomig (DRUG), 5-fluorouracil (DRUG).
Who is sponsoring clinical trial NCT06764875?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06764875 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Junction Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
RECRUITING · Phase 3
-
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RECRUITING · Phase 3
-
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
ACTIVE NOT RECRUITING · Phase 3
-
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
RECRUITING · Phase 2
Explore more on PlainTrial
Gastroesophageal Junction Adenocarcinoma
All registered trials for this condition
HER2-positive Gastric Cancer
All registered trials for this condition
Alaska
All trials with a study site in Alaska
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.